Results 51 to 60 of about 298,741 (199)

An Update on Human Papilloma Virus Vaccines: History, Types, Protection, and Efficacy

Frontiers in Immunology, 2022
Human papillomavirus (HPV) is the most common sexually transmitted agent worldwide. Early prevention with HPV vaccination is a safe and effective method against this disease.
Zahra Yousefi, Hamid Aria, Farhoodeh Ghaedrahmati, Tahereh Bakhtiari, Mahdieh Azizi, Reza Bastan, Reza Hosseini, Nahid Eskandari   +7 more
doaj   +1 more source

Genetic variants of EcPV2 E6 and E7 in equine genital and oronasal squamous cell carcinoma

Equine Veterinary Journal, EarlyView.
Abstract Background Since its discovery in 2008, equine papillomavirus type 2 (EcPV2) has been detected in up to 100% of equine genital and up to 40% of equine oronasal squamous cell carcinomas (SCCs). Preliminary sequence data point to the existence of EcPV2 E6 and E7 oncogene variants compared to the British reference sequence from 2008.
Maya Jenner, Sabine Brandt
wiley   +1 more source

Governing HPV-related carcinoma using vaccines: Bottlenecks and breakthroughs

Frontiers in Oncology, 2022
Human papillomavirus (HPV) contributes to sexually transmitted infection, which is primarily associated with pre-cancerous and cancerous lesions in both men and women and is among the neglected cancerous infections in the world.
Rahul Bhattacharjee, Lamha Kumar, Archna Dhasmana, Tamoghni Mitra, Abhijit Dey, Sumira Malik, Bonglee Kim, Rohit Gundamaraju   +7 more
doaj   +1 more source

HPV Genotype Distribution in Cervical Cancer and High‐Grade Lesions in Norway, and Early Vaccine Impact

International Journal of Cancer, EarlyView.
ABSTRACT All cases of invasive cervical cancer (ICC) and subsets of high‐grade cervical intraepithelial neoplasia grade 2 or 3 (CIN2/3) and adenocarcinoma in situ (AIS) in Norway are tested for 37 human papillomavirus (HPV) genotypes, within a mandatory national surveillance system.
Terese Bekkevold, Ida Laake, Berit Feiring, Kristiane Søreng, Gro Kummeneje Presthus, Glenny Cecilie Alfsen, Irene Kraus Christiansen, Mona Hansen, Hanne Kristiansen, Eirik Olsen, Torstein Gjølgali Frengen, Emily A. Burger, Christine Genieve Monceyron Jonassen, Lill Trogstad   +13 more
wiley   +1 more source

Controlled Trial of Cervical Cancer Screening Frequency Among Human Papillomavirus Vaccinated Women II: Cervical Pre‐Cancer End‐Points by Specific Non‐Vaccine HPV Types

International Journal of Cancer, EarlyView.
ABSTRACT We conducted a controlled trial among 5626 early adolescent women vaccinated in 2007–2009 against human papillomavirus (HPV) types 16/18 to evaluate the impact of high‐intensity versus low‐intensity cervical screening, respectively at ages 22/25/28 and 28 years with squamous‐cell intraepithelial lesions (SILs) as the end‐point.
Matti Lehtinen, Mònica Ortega Llobet, Tiina Eriksson, Iacopo Baussano, Miriam Elfström, Mehran Ghaderi, Penelope Gray, Katja Harjula, Kaisa Heikkilä, Mari Hokkanen, Saara Kares, Camilla Lagheden, Pekka Nieminen, Anna Söderlund‐Strand, Joakim Dillner, Ville N. Pimenoff   +15 more
wiley   +1 more source

An in depth study of human papillomavirus diversity in South African women infected with HIV [PDF]

, 2009
Includes abstract. Includes bibliographical references (leaves 109-129).Cervical cancer is the second most common cancer affecting women and in most developing countries it remains the leading cause of cancer deaths.
Salimo, Anna T
core   +1 more source

Cervical cancer prevention by vaccination: review

Frontiers in Oncology
Routine use of human papillomavirus (HPV) vaccines is recommended in adolescents under 15 years of age worldwide. Still, effective programs remain suboptimal for several factors, making the WHO strategy to eradicate cervical cancer public health with an ...
Julio Cesar González-Rodríguez, Aurelio Cruz-Valdez, Vicente Madrid-Marina   +2 more
doaj   +1 more source

Vaccinations in pregnancy: An update for a changing time

International Journal of Gynecology &Obstetrics, EarlyView.
Abstract Maternal immunization is one of the most effective public health interventions to reduce infectious morbidity and mortality in pregnant women, fetuses, and newborns. Despite robust evidence supporting vaccine safety and effectiveness in pregnancy, global uptake has declined following the COVID‐19 pandemic, contributing to resurgent outbreaks ...
Wendy Hodge, Méabh Bhuinneáin, Gelila Goba, Marisa Labovsky, Eliana Amaral, Asma Khalil, David Lissauer, Hema Divakar, Fionnuala M. McAuliffe, Deborah Money, Dharmintra Pasupathy, on behalf of the FIGO Committee on Infections During Pregnancy   +11 more
wiley   +1 more source

Therapeutic dendritic cell vaccination against human papillomavirus [PDF]

, 2009
Cervical cancer, which is caused by infection with human papillomavirus (HPV), is the second most common cancer among women worldwide, leading to 230000 deaths annually.
Nurkkala Karlsson, Merja
core   +1 more source

Clearance of high‐risk human papillomavirus in patients with cervical intraepithelial neoplasia 2–3 after the loop electrosurgical excision procedure with negative resection margins

International Journal of Gynecology &Obstetrics, EarlyView.
Abstract Objective This study aims to evaluate the longitudinal clearance rates of high‐risk human papillomavirus (hr‐HPV) and the incidence of clinical recurrence (defined by abnormal cytology or histologically confirmed cervical intraepithelial neoplasia; CIN) at 6 and 18 months post‐loop electrosurgical excision procedure (LEEP), characterizing the ...
Praew Sittichivapak, Pattama Chaopotong
wiley   +1 more source